Key facts
- It has raised $27.3M; the latest was Later Stage VC ($20.0M) in Jul 2025.
- Notable investors include Tech Incubator Program for Startup, STIC Ventures, Partners Investment, Bluepoint Partners, Korea Investment & Securities — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for NOBO Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for NOBO Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NOBO Medicine
Operator of a research and development company intended to provide risk analysis services for various diseases through molecular diagnosis. The company develops biomarkers through bioinformatics technology and performs precision medicine, such as diagnosis and targeted drug development, enabling healthcare workers to perform molecular diagnoses through technology and diverse experiences.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2017
- Employees
- 12
- Website
- nobomedicine.com/
- Ownership
- Privately Held (backing)
NOBO Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NOBO Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NOBO Medicine in its N-PORT filings yet. We sweep new filings monthly.